Palomid 529 (P529): Dual mTORC1/2 Inhibition for Cancer Rese
2026-06-11
Palomid 529 (P529) is a potent small-molecule inhibitor of both mTORC1 and mTORC2, with demonstrated efficacy in cancer models and radiotherapy enhancement. Its nanomolar potency against angiogenic pathways and stability profile make it a preferred tool for PI3K/Akt/mTOR pathway research. APExBIO supplies P529 as SKU A8618 for advanced oncology and neuroscience workflows.
2-Hydroxypropyl-β-cyclodextrin: Technical Solubility Guide
2026-06-11
2-Hydroxypropyl-β-cyclodextrin is a cyclic oligosaccharide excipient designed for solubilizing poorly water-soluble, hydrophobic compounds—especially those containing aromatic or phenyl groups—through inclusion complex formation. It is best utilized in pharmaceutical and biochemical research for solubility enhancement or as a drug formulation excipient; applications outside these validated uses are not supported by current product documentation.
Gamithromycin PK/PD in Bovine Respiratory Disease: PELF as a
2026-06-10
This study elucidates the pharmacokinetic and pharmacodynamic relationship of gamithromycin in plasma versus pulmonary epithelial lining fluid (PELF) in cattle with naturally occurring bovine respiratory disease. Its major finding is that PELF exposure indices, particularly AUC0–24/MIC, are more predictive of successful treatment outcomes against Pasteurella multocida, refining the understanding of tissue-targeted antibiotic efficacy.
HPF: Advancing hROS Detection in Multimodal Cancer Photother
2026-06-10
Explore how HPF (hydroxyphenyl fluorescein) empowers translational researchers to unravel highly reactive oxygen species dynamics in next-generation multimodal phototherapies, bridging mechanistic insights with protocol-ready guidance for reliable intracellular oxidative stress visualization.
FASN Inhibition Sensitizes Pancreatic Cancer to ABT-263-Indu
2026-06-09
This study demonstrates that inhibition of fatty acid synthase (FASN) enhances the effectiveness of BH3 mimetic drugs, including ABT-263 (Navitoclax), in overcoming resistance to mitochondrial apoptosis in pancreatic ductal adenocarcinoma (PDAC). The findings highlight a metabolic vulnerability in chemoresistant PDAC and provide a rationale for combination strategies targeting both lipid metabolism and Bcl-2 family proteins.
Practical Use of Oligo (dT) 25 Beads for mRNA Isolation
2026-06-09
Oligo (dT) 25 Beads (SKU K1306) enable efficient, selective isolation of polyadenylated mRNA from eukaryotic samples, supporting downstream workflows like RT-PCR and next-generation sequencing. They are not suitable for prokaryotic RNA or non-polyA nucleic acid purification. Researchers seeking high-integrity mRNA for molecular biology applications will find these superparamagnetic beads robust and reproducible.
Optimizing Gamithromycin Use for BRD: PK/PD Insights in Catt
2026-06-08
This study establishes precise pharmacokinetic and pharmacodynamic (PK/PD) targets for gamithromycin in the treatment of Pasteurella multocida infection in cattle. By leveraging a tissue cage model, the research identifies AUC0-24h/MIC thresholds for bacteriostatic, bactericidal, and eradication effects, providing a scientific basis for dosing optimization and resistance mitigation.
CX-5461 (SKU A8337): Reliable RNA Polymerase I Inhibitor Sol
2026-06-08
This article provides a scenario-driven, evidence-backed guide to deploying CX-5461 (SKU A8337) in cancer research workflows. Drawing on recent literature and the unique formulation of this Pol I-driven rRNA synthesis inhibitor, we address common experimental challenges, protocol optimization, and product reliability. Researchers will find actionable strategies for enhancing cell viability, proliferation, and cytotoxicity assays with CX-5461.
Optimizing hiPSC-Derived Platelet Production with Small Mole
2026-06-07
This study presents a systematically optimized protocol for differentiating human induced pluripotent stem cells (hiPSCs) into functional platelets, leveraging higher embryoid body input, refined medium, and strategic small molecule substitution. The approach reduces costs, enhances yield, and accelerates production, providing a practical platform for scalable cell therapy and gene editing applications.
Docosahexaenoic Acid (DHA): Molecular Roles in Synaptic, Vis
2026-06-06
Explore the multifaceted roles of Docosahexaenoic Acid (DHA) in neural, retinal, and emerging immune pathways. This in-depth article analyzes DHA’s molecular mechanisms, its anti-inflammatory omega-3 potential, and bridges foundational research to practical experimental use.
Calpain Inhibitor I, ALLN: Technical Workflow Guidance
2026-06-05
Calpain Inhibitor I (ALLN) targets calpain and cathepsin proteases, enabling selective inhibition in apoptosis and ischemia-reperfusion injury models. This article outlines technical handling, solubility, and workflow integration for research use, emphasizing precise application boundaries and reducing common experimental pitfalls.
PKH26 Red Fluorescent Cell Linker Kit: Technical Guide & Pro
2026-06-05
The PKH26 Red Fluorescent Cell Linker Kit enables stable and minimally cytotoxic cell membrane labeling for long-term cell tracing and proliferation detection in vitro and in vivo. This solution is not suitable for intracellular or non-membrane applications, and reliable results require adherence to protocol parameters and workflow best practices.
5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB): New Fro
2026-06-04
Discover how 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) is redefining transcriptional elongation research by bridging classical CDK inhibition with emerging insights from epitranscriptomic studies. This article provides advanced mechanistic analysis, practical protocol guidance, and an original perspective that moves beyond standard workflows.
LDN-193189 in Intestinal Epithelial Homeostasis: Mechanisms
2026-06-04
Explore how LDN-193189, a potent ALK inhibitor, modulates BMP signaling to protect intestinal epithelial function. This article uniquely dissects its mechanistic application in epithelial homeostasis, referencing pivotal research and offering advanced protocol guidance.
AURKB Inhibition as a Novel Strategy for Pulmonary Hypertens
2026-06-03
Lemay et al. identify Aurora kinase B (AURKB) as a therapeutic target in pulmonary arterial hypertension (PAH) by integrating transcriptomic analysis with preclinical models. Their work demonstrates that AURKB inhibition curbs PASMC proliferation and vascular remodeling, offering a mechanistically grounded approach for future PAH therapies.
466 records 16/32 page Previous Next First page 上5页 1617181920 下5页 Last page